AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

ASP Isotopes Inc. Common Stock

$3.19 -$2.44 (-43.34%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$3.31
Day Range
$3.18$3.31
Year Range
$3.18$14.49
Market Cap
401.63M
AVG Volume
4.53M
Trailing/Forward PE
-2.42/-
PEG ratio
0.08
Dividend Yield
-
Next Earnings Date
2026-11-12
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
010M20M30M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q230.85M
26 Q126.93M
25 Q423.85M
25 Q38.38M
25 Q24.58M
25 Q14.41M
24 Q44.14M
24 Q33.38M
24 Q22.3M
24 Q11.27M
Net Income (USD) · TTM
-200M-150M-100M-50M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-132.05M
26 Q1-173.52M
25 Q4-175.09M
25 Q3-105.56M
25 Q2-99.96M
25 Q1-33.83M
24 Q4-32.33M
24 Q3-27.31M
24 Q2-24.27M
24 Q1-19.62M
Operating Income (USD) · TTM
-100M-75M-50M-25M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-96.35M
26 Q1-74.13M
25 Q4-57.19M
25 Q3-42.54M
25 Q2-33M
25 Q1-28.49M
24 Q4-26.35M
24 Q3-22.73M
24 Q2-21.24M
24 Q1-18.13M
EBITDA (USD) · TTM
-200M-150M-100M-50M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-129.15M
26 Q1-170.61M
25 Q4-157.07M
25 Q3-104.06M
25 Q2-98.78M
25 Q1-32.98M
24 Q4-31.58M
24 Q3-26.77M
24 Q2-23.9M
24 Q1-19.53M
Cash Flows (USD) · TTM
-100M-75M-50M-25M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-83.58M
26 Q1-65.8M
25 Q4-47.43M
25 Q3-33.96M
25 Q2-31.28M
25 Q1-29.38M
24 Q4-28.07M
24 Q3-24.49M
24 Q2-16.5M
24 Q1-10.15M
EPS (USD) · TTM
-3-2-1024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-1.32
26 Q1-2.08
25 Q4-2.14
25 Q3-1.46
25 Q2-1.43
25 Q1-0.64
24 Q4-0.68
24 Q3-0.61
24 Q2-0.63
24 Q1-0.53
Expenses (USD) · TTM
050M100M150MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q2117.78M
26 Q192.3M
25 Q470.25M
25 Q354.74M
25 Q246.41M
25 Q142.62M
24 Q439.33M
24 Q333.36M
24 Q227.77M
24 Q121.76M
Shares Outstanding · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASPI Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-14.12M
26 Q1-18.55M
25 Q4-16.02M
25 Q3-13.06M
25 Q2-10.65M
25 Q1-8.74M
24 Q4-8.56M
24 Q3-8.45M
24 Q2-8.46M
24 Q1-8.31M
Employee Count
01002003002022202320242025
ASPI Employee Count by quarter
PeriodEmployee Count
2025271
2024136
202376
202231
Free Cash Flow Yield
-25%-20%-15%-10%-5%0%med -6.9%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
ASPI Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-21.35%
Sep 26-20.58%
Sep 26-16.22%
Aug 26-17.55%
Aug 26-17.03%
Aug 26-15.95%
Aug 26-12.28%
Jul 26-13.6%
Jul 26-14.05%
Jul 26-14.02%
Jul 26-10.85%
Jul 26-9.66%
Jun 26-8.81%
Jun 26-7.57%
Jun 26-8.3%
Jun 26-8.1%
May 26-6.99%
May 26-9.8%
May 26-8.74%
May 26-9.42%
May 26-9.84%
Apr 26-9.47%
Apr 26-9.44%
Apr 26-11.31%
Apr 26-8.94%
Mar 26-8.78%
Mar 26-9.09%
Mar 26-7.26%
Mar 26-6.91%
Feb 26-7.18%
Feb 26-7.38%
Feb 26-7.35%
Feb 26-6.59%
Jan 26-6.05%
Jan 26-4.52%
Jan 26-4.96%
Jan 26-5.11%
Jan 26-6.81%
Dec 25-6.66%
Dec 25-6.31%
Dec 25-6.46%
Dec 25-5.86%
Nov 25-6.17%
Nov 25-6.42%
Nov 25-5.28%
Nov 25-4.76%
Oct 25-4.23%
Oct 25-4.36%
Oct 25-4.28%
Oct 25-4.23%
Oct 25-4.59%
Sep 25-4.06%
Sep 25-4.35%
Sep 25-4.89%
Sep 25-5.22%
Aug 25-4.62%
Aug 25-4.58%
Aug 25-4.6%
Aug 25-4.54%
Aug 25-4.74%
Jul 25-4.04%
Jul 25-4.03%
Jul 25-5.62%
Jul 25-6.06%
Jun 25-5.71%
Jun 25-5.59%
Jun 25-5.24%
Jun 25-4.52%
May 25-5.59%
May 25-4.92%
May 25-5.25%
May 25-5.95%
May 25-6.56%
Apr 25-7.49%
Apr 25-6.81%
Apr 25-6.64%
Apr 25-9.02%
Mar 25-9.52%
Mar 25-9.5%
Mar 25-9.41%
Mar 25-9.02%
Feb 25-8.36%
Feb 25-8.34%
Feb 25-7.52%
Feb 25-6.43%
Jan 25-6.92%
Jan 25-5.85%
Jan 25-7.03%
Jan 25-8.84%
Jan 25-7.41%
Dec 24-8.26%
Dec 24-8.14%
Dec 24-7.96%
Dec 24-8.65%
Nov 24-7.17%
Nov 24-4.77%
Nov 24-4.62%
Nov 24-3.83%
Nov 24-4.31%
Oct 24-6.88%
Price to Sales
050100150200med 85.11Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
ASPI Price to Sales by quarter
PeriodPrice to Sales
Sep 2612.69
Sep 2613.17
Sep 2616.71
Aug 2615.43
Aug 2615.91
Aug 2616.98
Aug 2619.91
Jul 2617.97
Jul 2617.39
Jul 2617.44
Jul 2622.51
Jul 2625.3
Jun 2627.73
Jun 2632.26
Jun 2629.43
Jun 2630.15
May 2634.96
May 2624.94
May 2622.77
May 2621.12
May 2620.22
Apr 2621
Apr 2621.08
Apr 2617.59
Apr 2645.31
Mar 2646.16
Mar 2644.58
Mar 2655.77
Mar 2658.62
Feb 2656.41
Feb 2654.93
Feb 2655.14
Feb 2661.48
Jan 2666.97
Jan 2689.57
Jan 2681.76
Jan 2679.33
Jan 2659.47
Dec 2560.84
Dec 2564.22
Dec 2562.74
Dec 2569.08
Nov 2565.7
Nov 2563.06
Nov 25129.24
Nov 25143.42
Oct 25161.43
Oct 25156.49
Oct 25159.52
Oct 25161.43
Oct 25148.84
Sep 25168.12
Sep 25157.13
Sep 25139.76
Sep 25130.83
Aug 25147.88
Aug 25149
Aug 25148.36
Aug 25147
Aug 25140.85
Jul 25165.14
Jul 25165.45
Jul 25118.61
Jul 25110.09
Jun 25116.71
Jun 25119.4
Jun 25127.28
Jun 25147.63
May 25119.24
May 25135.48
May 25137.88
May 25121.62
May 25110.27
Apr 2596.57
Apr 25106.21
Apr 25108.94
Apr 2580.2
Mar 2576.02
Mar 2576.2
Mar 2576.93
Mar 2580.2
Feb 2586.57
Feb 2586.75
Feb 2596.21
Feb 25112.58
Jan 25104.57
Jan 25123.67
Jan 25102.94
Jan 2581.84
Jan 2597.66
Dec 2487.66
Dec 2488.93
Dec 2490.93
Dec 2483.66
Nov 24100.94
Nov 24151.68
Nov 24155.6
Nov 24187.71
Nov 24166.73
Oct 24104.45
Price to Book
010203040med 6.98Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
ASPI Price to Book by quarter
PeriodPrice to Book
Sep 261.42
Sep 261.48
Sep 261.88
Aug 261.73
Aug 261.79
Aug 261.91
Aug 261.79
Jul 261.62
Jul 261.57
Jul 261.57
Jul 262.03
Jul 262.28
Jun 262.5
Jun 262.91
Jun 262.65
Jun 262.72
May 263.15
May 262.25
May 262.07
May 261.92
May 261.83
Apr 261.91
Apr 261.91
Apr 261.6
Apr 263.93
Mar 264.01
Mar 263.87
Mar 264.84
Mar 265.09
Feb 264.89
Feb 264.77
Feb 264.78
Feb 265.33
Jan 265.81
Jan 267.77
Jan 267.09
Jan 266.88
Jan 265.16
Dec 255.28
Dec 255.57
Dec 255.44
Dec 255.99
Nov 255.7
Nov 255.47
Nov 2520.91
Nov 2523.21
Oct 2526.12
Oct 2525.32
Oct 2525.81
Oct 2526.12
Oct 2524.09
Sep 2527.21
Sep 2525.43
Sep 2522.62
Sep 2521.17
Aug 2523.93
Aug 2524.11
Aug 2524.01
Aug 2514.16
Aug 2513.57
Jul 2515.91
Jul 2515.94
Jul 2511.43
Jul 2510.61
Jun 2511.24
Jun 2511.5
Jun 2512.26
Jun 2514.22
May 2511.49
May 2513.05
May 2510.07
May 258.88
May 258.05
Apr 257.78
Apr 258.55
Apr 258.77
Apr 256.46
Mar 256.12
Mar 256.14
Mar 256.2
Mar 256.46
Feb 256.97
Feb 256.99
Feb 257.75
Feb 259.07
Jan 258.42
Jan 259.96
Jan 258.29
Jan 256.59
Jan 257.87
Dec 247.06
Dec 247.16
Dec 247.32
Dec 246.74
Nov 248.13
Nov 2412.22
Nov 2424.87
Nov 2430
Nov 2426.65
Oct 2416.7
ASP Isotopes Inc. Common Stock
ASPI
Stockpicker

Video analysis: ASPI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ASPI

ASP Isotopes Inc. (ASPI) Analyst/Investor Day Transcript

seekingalpha.com · 9 Sep 2026

ASP Isotopes Inc. (ASPI) Analyst/Investor Day Transcript

ASP Isotopes Inc. (ASPI) Analyst/Investor Day Transcript

ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Update

globenewswire.com · 8 Sep 2026

ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Update

DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for critical materials production, today hosts its inaugural Capital Markets Day in London. Management will outline the Company's strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels, and will provide an overview of the building blocks supporting the Company's long-term growth potential.

BlackRock Inc. Purchases Shares of 9,217,198 ASP Isotopes Inc. $ASPI

defenseworld.net · 1 Sep 2026

BlackRock Inc. Purchases Shares of 9,217,198 ASP Isotopes Inc. $ASPI

BlackRock Inc. acquired a new stake in shares of ASP Isotopes Inc. (NASDAQ: ASPI) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,217,198 shares of the company's stock, valued at approximately $57,331,000. BlackRock Inc. owned about 6.01% of ASP Isotopes as of

ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth

marketbeat.com · 21 Aug 2026

ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth

ASP Isotopes NASDAQ: ASPI expects several of its business units to enter commercial production or expand output over the next six months, with Chief Executive Officer Paul Mann highlighting progress in helium, liquefied natural gas, stable isotopes and radiopharmaceuticals during a conference presentation.

ASP Isotopes Inc. Announces that Renergen Limited's Subsidiary has Commenced Commissioning of Liquid Helium Plant in South Africa

globenewswire.com · 20 Aug 2026

ASP Isotopes Inc. Announces that Renergen Limited's Subsidiary has Commenced Commissioning of Liquid Helium Plant in South Africa

Tetra4, a subsidiary of Renergen and the developer of the Virginia Gas Project, has started the commissioning phase of the Phase 1 Liquid Helium plant post engineering optimization The production is expected to be among the first new liquid helium supply to enter the market at a time of acute global shortage The Company remains on track to deliver liquid helium to customers during September and ramp production to nameplate capacity during 2H Following the successful start-up of Phase 1, the Company expects to advance to Phase 2 during 2H 2026. The Company is currently exploring ways to accelerate the revenues and cash flows from Phase 2 DALLAS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today announced that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited (“Renergen”) and the developer of the Virginia Gas Project, has entered the commissioning phase of the Company's liquid helium plant.

Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream

globenewswire.com · 19 Aug 2026

Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.

ASP Isotopes Announces Quantum Leap Energy is Evaluating Metal Conversion Opportunities in Namibia

globenewswire.com · 18 Aug 2026

ASP Isotopes Announces Quantum Leap Energy is Evaluating Metal Conversion Opportunities in Namibia

DALLAS, Aug. 18, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that Quantum Leap Energy LLC (“we,” "QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, is evaluating metal conversion opportunities in Namibia. As part of this evaluation, a public environmental and social impact assessment and consultation process has commenced for a proposed pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area of Namibia.

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

businesswire.com · 17 Aug 2026

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”) , R.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.